Sociedad Americana de Hirudoterapia

Anticoagulant peptide LR from Whitmania pigra ameliorates cerebral ischemia-reperfusion injury

Preclinical study published in Brain Research (2026)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaFarmacología salivalDesarrollo de fármacosLiu R et al. · Brain research, 2026

Abstract

BACKGROUND: Ischemic stroke (IS) is a leading cause of death and disability worldwide. Hypercoagulability and thrombus formation play critical roles in its pathogenesis. Leech-derived peptides, especially those obtained from Whitmania pigra, have demonstrated potential antithrombotic and neuroprotective effects. This study aimed to investigate the therapeutic efficacy and underlying mechanisms of a leech peptide in a rat model of cerebral ischemia/reperfusion injury. METHODS: Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion followed by reperfusion to establish the IS model. Rats received low-dose or high-dose leech peptide, edaravone as a positive control, or saline. Behavioral assessments, infarct volume measurement, laser speckle imaging for cerebral perfusion, and histopathology were performed. Hemorheology and coagulation parameters were analyzed. Additionally, thrombin levels and fibrinolytic factors were evaluated using ELISA. Biosafety was assessed through hemolysis and histological evaluation of major organs. RESULTS: Leech peptide significantly reduced infarct volume, improved neurological scores, enhanced cerebral perfusion, and preserved brain tissue structure. It modulated thrombin-related parameters, ameliorated coagulation dysfunction, and modulated fibrinolysis-associated factors, thereby contributing to the restoration of coagulation-fibrinolysis homeostasis. Low-dose treatment showed comparable or superior efficacy to the high dose with better safety. No significant toxicity or hemolysis was observed. CONCLUSIONS: Leech peptide derived from Whitmania pigra exerts neuroprotective effects in cerebral ischemia/reperfusion injury through anticoagulation and thrombolysis. These findings support its potential as a novel candidate for IS therapy. TRIAL REGISTRATION: Not applicable. This study did not involve human participants.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsRats, Sprague-DawleyMaleReperfusion InjuryRatsLeechesNeuroprotective AgentsAnticoagulantsPeptidesBrain IschemiaDisease Models, AnimalInfarction, Middle Cerebral Artery

Resumen

Anticoagulant peptide LR from Whitmania pigra reduces infarct volume and improves neurological scores in murine cerebral ischemia-reperfusion model via thrombin inhibition.

Por qué esto importa para la hirudoterapia

This study investigated the therapeutic efficacy of a leech-derived peptide from Whitmania pigra in a rat model of cerebral ischemia/reperfusion injury (middle cerebral artery occlusion), assessing neurological scores, infarct volume, cerebral perfusion via laser speckle imaging, hemorheology, coagulation parameters, thrombin levels, and fibrinolytic factors. The leech peptide significantly reduced infarct volume, improved neurological scores and cerebral perfusion, modulated thrombin-related parameters and fibrinolysis, and restored coagulation-fibrinolysis homeostasis, with the low dose showing comparable or superior efficacy and no significant toxicity or hemolysis. These findings are relevant to hirudotherapy as they demonstrate neuroprotective and antithrombotic effects of a specific leech peptide in a stroke model. However, this study was conducted exclusively in rats; no human data are presented, and clinical translation would require further validation.

Citación

Anticoagulant peptide LR from Whitmania pigra ameliorates cerebral ischemia-reperfusion injury.

Liu R et al. · Brain research, 2026

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.